Amedisys Inc (NASDAQ:AMED) was downgraded by equities researchers at Mizuho from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, The Fly reports.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $57.00 target price on shares of Amedisys in a report on Friday, April 28th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 price target on shares of Amedisys in a report on Monday, June 5th. Stephens raised their price target on Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a report on Thursday, May 4th. Finally, Benchmark Co. reaffirmed a “hold” rating and set a $57.00 price target (up from $50.00) on shares of Amedisys in a report on Wednesday, May 3rd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $58.38.

Amedisys (NASDAQ:AMED) opened at 59.41 on Wednesday. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The firm’s 50-day moving average price is $61.62 and its 200-day moving average price is $53.96. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of 44.01 and a beta of 0.94.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, May 2nd. The health services provider reported $0.47 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.06. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. The business had revenue of $370.46 million during the quarter, compared to analysts’ expectations of $370.03 million. During the same period in the prior year, the firm posted $0.33 EPS. Equities research analysts predict that Amedisys will post $2.08 earnings per share for the current year.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/26/amedisys-inc-nasdaqamed-downgraded-to-neutral-at-mizuho.html.

In related news, insider Scott G. Ginn sold 23,828 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $58.62, for a total transaction of $1,396,797.36. Following the completion of the sale, the insider now directly owns 13,018 shares of the company’s stock, valued at approximately $763,115.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lawrence R. Pernosky sold 11,500 shares of the firm’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $58.78, for a total value of $675,970.00. Following the sale, the insider now directly owns 30,093 shares of the company’s stock, valued at $1,768,866.54. The disclosure for this sale can be found here. Insiders have sold a total of 56,828 shares of company stock valued at $3,350,922 over the last ninety days. Insiders own 2.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in AMED. Russell Investments Group Ltd. purchased a new position in shares of Amedisys during the fourth quarter worth approximately $870,000. Thrivent Financial for Lutherans raised its position in shares of Amedisys by 6.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 15,133 shares of the health services provider’s stock worth $645,000 after buying an additional 880 shares during the last quarter. Norges Bank purchased a new position in shares of Amedisys during the fourth quarter worth approximately $13,483,000. Hudson Bay Capital Management LP purchased a new position in shares of Amedisys during the fourth quarter worth approximately $1,066,000. Finally, Bank of Montreal Can raised its position in shares of Amedisys by 8,881.4% in the first quarter. Bank of Montreal Can now owns 34,848 shares of the health services provider’s stock worth $1,780,000 after buying an additional 34,460 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

The Fly

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.